Latest Headlines

Latest Headlines

Analyst: New obstacles for Perrigo's businesses could thwart Mylan's deal logic

Some analysts have never been all that keen on Mylan's hostile quest for Perrigo. But some forthcoming obstacles for Perrigo's businesses now have at least one questioning the deal's logic even further.

Perrigo licenses Flamel's oral suspension delivery platform to develop additional OTC meds

As part of its so-called Base Plus Plus Plus strategy, specialty pharmaceutical company Perrigo announced that it is licensing Flamel's LiquiTime extended-release suspension to develop products for the U.S. over-the-counter market.

Perrigo brings Mylan takeover feud to Israeli court

Mylan and its hostile takeover target, Perrigo, have been trading lawsuits in the U.S., but now they've taken their legal battle across the ocean.

Mylan fires back at Perrigo lawsuit with counterclaims of 'misleading' statements

Mylan and Perrigo's warring words have turned into warring lawsuits. After Perrigo sued last week to block Mylan's proposed takeover, saying the would-be buyer had misled shareholders, Mylan countersued, alleging its own set of "false and misleading statements."

Perrigo CEO has slammed Mylan for months--but he owns its shares

Perrigo CEO Joseph Papa has cautioned investors against taking up an offer from hostile suitor Mylan. But Papa is already a Mylan shareholder himself.

Perrigo officially rejects Mylan's 'insulting,' 'ego'-driven buyout offer

Surprise, surprise. Perrigo, which has staunchly opposed suitor Mylan's buyout offers since the company first expressed interest back in April, has officially advised shareholders to shoot down the would-be buyer's proposal.

Perrigo racks up more opposition to Mylan's now-official hostile bid

It's official: Mylan has taken its Perrigo buyout offer to the Irish company's shareholders. But plenty of industry-watchers are still opposed to the idea.

Just wait, Perrigo investor urges. We can get the same return--without a Mylan deal

All eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli businessman Mori Arkin, for one, plans to deliver a resounding "no."

Perrigo's fate is in shareholders' hands, Mylan chairman says. Or is it?

With the go-ahead from its own shareholders, Mylan is now pushing full steam ahead to acquire Perrigo--and as Chairman Robert Coury wrote in a Tuesday letter to its Irish target's CEO, "you and your board are now unable to stop the combination."

UPDATED: Mylan shareholders OK hostile run at Perrigo

Mylan's shareholders think it is a dandy idea to continue to pursue a takeover of Perrigo. Two thirds of those who voted today favored pursuing the buyout of over-the-counter specialist despite the adamant opposition to the deal from Perrigo CEO Joseph Papa and his board.